Microdosing: the no-flowers-in-your-hair practice of taking minimal amounts (fractions of a gram) of hallucinogenic substances like psilocybin mushrooms or LSD, on a regular basis. Individuals who microdose claim to experience an elevated mood, increased productivity, and a greater capacity for creativity – without suffering the hallucinogenic effects that many would consider debilitating. Although it’s currently illegal in the U.S., early research into its effects are demonstrating positive results and millions of dollars are being poured into further research. See the full article on microdosing mushrooms and LSD here:
https://www.freethink.com/videos/microdosing
On MISTER TACHYON: Micro-dosing has been on the rise. But does really it work? Where’s Hamilton when you need him?
Leading psychopharmacologist Roland Griffiths discloses the ways that psychedelic drugs can be used to create spiritually meaningful, personally transformative experiences for all patients, especially the terminally ill.
A clinical psychologist from Imperial College describes how Magic Mushrooms (Psilocybin), when used in a therapeutic setting, have been found to be a very effective treatment for depression. In this talk she draws on her experiences as working as a therapist on the groundbreaking Psilocybin for Depression study, and introduces us to some of the patients and their stories of transformation. Dr Rosalind Watts completed her clinical psychology training at University College London. After six years of practicing psychotherapy in the NHS, she joined a clinical trial at Imperial College, investigating psilocybin (magic mushrooms) as a treatment for depression. Her research explores patients’ positive views of this intriguing therapy. This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at http://ted.com/tedx
Kathleen Conneally successfully quit smoking, after a decades-long habit, with the help of psilocybin. Conneally was a participant in a study at Johns Hopkins University looking at whether nicotine addiction could be treated by psilocybin, the active compound in magic mushrooms. In this short video, staff writer Olga Khazan speaks with Conneally about her experience and uncovers the science of how psychedelics work in the brain to make this possible.
Can micro-dosing psychedelic drugs help with certain mental illness and disabilities? Facebook: https://www.facebook.com/thefeedsbsvi… Twitter: https://twitter.com/thefeedsbs Insta: https://instagram.com/thefeedsbs
“The Multidisciplinary Association for Psychedelic Studies (MAPS) Canada envisions a world where psychedelics and marijuana are safely and legally available for beneficial uses, and where research is governed by a rigorous scientific evaluation of their risks and benefits.”
“Canada’s premier conference on psychedelic psychotherapy. The Forum engages mental health professionals and all others interested in advancing the ethical and legal use of psychedelic and plant medicines for healing, personal growth and transformation.”
“A community of communities with a multidisciplinary interest in the science, healing, education, and business of psychedelics. Join us for our events around the city.”
New York University, January 2013
“Patients who have benefited from psilocybin clinical research have reported less anxiety, improved quality of life, enhanced psychological and spiritual well-being, and a greater acceptance of the life-changes brought on by cancer.”
The Lancet, May 2016
“Psilocybin was well tolerated by all of the patients, and no serious or unexpected adverse events occurred. Relative to baseline, depressive symptoms were markedly reduced 1 week and 3 months after treatment. Marked and sustained improvements in anxiety and anhedonia were also noted.”
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer.
Journal of Psychopharmacology, November 2016
“…psilocybin produced immediate, substantial, and sustained improvements in anxiety and depression and led to decreases in cancer-related demoralization and hopelessness, improved spiritual wellbeing, and increased quality of life.”
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.
Journal of Psychopharmacology, November 2016
“…psilocybin produced large decreases in clinician- and self-rated measures of depressed mood and anxiety, along with increases in quality of life, life meaning, and optimism, and decreases in death anxiety. At 6-month follow-up, these changes were sustained…”
Popular Science, May 2017
“If you’re looking to play it safe when it comes to illicit substances, look no further than the humble shroom. It’s non-addictive, hard to overdose on, and you can grow it yourself. And, according to a massive report by the Global Drug Survey, it sends the fewest people to the emergency room of any drug on the market.”
Journal of Palliative Medicine, April 2018
“With an expanding evidence base confirming safety and benefits… it is time to revisit the legitimate therapeutic use of psychedelics.”
An interview study of psychedelic microdosing.
Nordic Studies on Alcohol and Drugs, February 2018
“Respondents generally agreed that proper microdoses did not result in any intoxication. The majority reported some effect that they regarded as positive. The most commonly described effects were health-related, with a benign influence noted especially on states of depression and anxiety.”
“Therapeutic effect was also reported for pain management and for a range of conditions including obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), narcolepsy, and migraines.”
Refinery 29, December 2015
“I’m on mushrooms right now. Just a small amount, about half the size of my pinky nail. I’m not hallucinating or anything, but for the past couple of months, I’ve been taking a regular, tiny dose of psilocybin ‘shrooms every few days. And life has never been better. It’s called “microdosing” — and, so far, it’s been awesome.”
The Guardian, December 2016
“Immediate reduction in depression and anxiety for up to eight months seen in patients with advanced cancer given a single dose of psilocybin.”
Huffington Post, January 2016
“Fadiman is examining the effects of administering psychedelic drugs like LSD and psilocybin in amounts so small that they are below the perceptual threshold. As part of an ongoing research project, Fadiman is collecting the self-reported testimonies of hundreds of people from around the globe.”
The Cut, December 2016
“In a surprising number of cases, a single dose of psilocybin can lead to lasting improvements to mental health and the abatement of serious psychological issues.”
Better Humans, September 2017
“My perspective on psychedelics quickly changed, and they became a vehicle for greater self-reflection and awareness. Psychedelics appealed to me in their ability to work through painful emotions of the past.”
Third Wave, January 2017
“Recently, psychiatrists and therapists have turned to the classic psychedelic psilocybin as a potential salve for end-of-life anxiety. Psychiatrists have known for half a century that classic psychedelics often provide a new perspective on life, as a result of the peak/mystical experience.”
Psychology Today, May 2017
“Psychedelic drugs are in the vanguard of treatment for addiction, raising the paradoxical question of how one mind-altering substance can override dependence on another.”
Scientific American, August 2018
“Dennis van der Meijden isn’t aiming to see the face of God, feel one with the cosmos, grasp the hidden reality of time and space, or embark on a sacred journey. What the Dutch graphic designer, producer, and rapper wants — and gets — from his twice-weekly ‘microdoses’ of psilocybin is more modest.”
Alternet, November 2018
“A pair of Canadian researchers have just completed a study comparing people who microdose—the act of taking very small quantities of psychedelic drugs such as LSD or magic mushrooms—with those who don’t. They found that microdosers scored higher on key measures of mental health and well-being.”
Vice, November 2018
“Two Ph.D. students in Ontario conducted one of the first-ever studies on microdosing. They found that some of what microdosers rave about seems to hold true.
CBC News, February 2018
“Shaw expects to have results of her survey within a few months, but she has been struck by the overwhelmingly positive and sometimes transformative experiences with magic mushrooms that people have described to her”
Globe & Mail, June 2018
“Researchers are examining the potential of drugs like LSD and psilocybin – recreational drugs most associated with the 1960s counterculture – to act as psycho-therapeutic tools in the treatment of severe addictions, end-of-life anxiety, depression, and post-traumatic stress disorder. Truth be told, many of the new findings are in fact old discoveries.”
Georgia Straight, January 2018
“The B.C. Centre on Substance Use has assembled a team that’s positioning Vancouver as a global force in investigating mind-altering drugs for the treatment of addiction and mental disorders.”
CBC News, August 2018:
“They found that microdosers scored higher on both creativity and wisdom, and lower on negative emotionality and dysfunctional attitude tied to depression and anxiety.”
Medium, May 2018
“If someone said you could take a simple drug that in five hour’s time would not only reset your brain, erasing years of depressive and anxious feelings but also generally lift your mood, seemingly permanently, would you do it? I did.”
The Cut, May 2018
“Consuming crumb-size amounts of psychedelics — not to get high but to feel more focused and creative and present — has moved a tiny bit mainstream.”